Supplementary Table 2 from Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer
Niki Gavrielatou(National and Kapodistrian University of Athens), David L. Rimm(Yale University), Kurt A. Schalper(Yale University), Aileen I. Fernandez(Yale University), Amanda Psyrri(National and Kapodistrian University of Athens), Jon Zugazagoitia(Instituto de Salud Carlos III), Saba Shafi(Ministry of Education of the People's Republic of China), Ioannis Vathiotis(Yale University), Yuting Liu(University of California San Diego), Thazin Nwe Aung(Yale University)
Cited by 0
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753